Deshawn "DJ" Chow's Casgevy Treatment

This is a the United States news story, published by Wired, that relates primarily to Casgevy news.

the United States news

For more the United States news, you can click here:

more the United States news

Casgevy news

For more Casgevy news, you can click here:

more Casgevy news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Wired news

For more news from Wired, you can click here:

more news from Wired

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

first sickle cell patient

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest sickle cell disease news, sickle cell news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

sickle cell patients

Wired

•

Health

The World’s First Crispr Drug Gets a Slow Start

Summary

Nutrition label

77% Informative

Deshawn "DJ" Chow was born with sickle cell disease, which makes his red blood cells crescent-shaped and sticky.

The condition affects about 100,000 people in the United States , most of them Black.

A year ago , he found out about a new treatment called Casgevy that could end his years -long battle with pain.

Deshawn “DJ” Chow, 19 , gets infused with Casgevy with pediatric hematologist-oncologist Dr Leo Wang .

Sickle cell disease arises from errors in a gene that makes hemoglobin, the substance that carries oxygen throughout the body and gives red blood cells their color.

Patients must undergo a high dose of chemotherapy to make space in the bone marrow for the edited stem cells.

Casgevy involves editing a patient’s stem cells with Crispr and returning them to the body.

The drug is a $2.2 million drug, which is just the cost of the medicine.

Hospitals are also dealing with insurance hiccups. Navigating state Medicaid programs is another challenge.

VR Score

Informative language

Neutral language

Article tone

semi-formal

Language

English

Language complexity